Pulmonary Hypertension

Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

By

Patients with suspected PH should undergo two 6MWTs to improve the accuracy of exercise capacity measurements.

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

By

The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.

Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

By

Individuals treated with riociguat for pulmonary hypertension may have a greater risk for gastrointestinal disorders compared with tadalafil and sildenafil.

Pulmonary Arterial Hypertension: Improving Survival Rates

Pulmonary Arterial Hypertension: Improving Survival Rates

By

Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.

Thyroid hormone supplementation may be a promising treatment for idiopathic pulmonary fibrosis [PreClinical]

An enzyme involved in thyroid hormone activation was found to be elevated in patients with pulmonary fibrosis.

Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

By

Although the Wells and revised Geneva scores are used in the general population to predict pulmonary embolism, researchers found they were not reliable in pregnant and postpartum women.

Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

By

Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

By

Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.

New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

By

A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.

REVEAL Risk Score for Long-Term Outcomes in PAH

REVEAL Risk Score for Long-Term Outcomes in PAH

By

The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.

PAH: Implantable Treprostinil Delivery System Is Promising

PAH: Implantable Treprostinil Delivery System Is Promising

By

A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

By

Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

By

A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.

Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

By

Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.

Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

By

A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.

Veno-Arterial Extracorporeal Membrane Oxygenation Effective for Massive PE

Veno-Arterial Extracorporeal Membrane Oxygenation Effective for Massive PE

By

The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

By

A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

By

Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.

Increasing 6-Minute Walking Distance in Peripheral Artery Disease

Increasing 6-Minute Walking Distance in Peripheral Artery Disease

Study results confirm the benefits of exercise vs granulocyte-macrophage colony-stimulating factor in improving 6-minute walk test in PAD.

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

By

Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

By

Pulmonary and thoracic symptoms often coincide with initial presentation of connective tissue disease.

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

By

Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

By

Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.

Impaired Cerebral Pressure-Flow Relationship in PAH

Impaired Cerebral Pressure-Flow Relationship in PAH

By

Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

By

Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.

Redesigned Inhalation Device for PAH Approved by FDA

Redesigned Inhalation Device for PAH Approved by FDA

By

The new device features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, a rechargeable battery, and a display that guides patients through the inhalation process.

Phenotypes Associated With <i>EIF2AK4</i> Mutations in PAH

Phenotypes Associated With EIF2AK4 Mutations in PAH

By

The frequency of eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) mutations in patients with pulmonary arterial hypertension was investigated.

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Borderline PH was linked to increased mortality after adjustment for 34 variables.

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

By

Pulmonary vascular compliance may independently predict survival and prognosis in patients with pulmonary arterial hypertension associated with congenital heart disease.

Bronchoalveolar Lavage for Diagnosis of Idiopathic Pulmonary Fibrosis: Point/Counterpoint

Bronchoalveolar Lavage for Diagnosis of Idiopathic Pulmonary Fibrosis: Point/Counterpoint

By

Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.

Sign Up for Free e-newsletters